Andere Kunden interessierten sich auch für
![Novel Molecular Biomarkers For Breast Cancer Diagnosis And Prognosis]( "Novel Molecular Biomarkers For Breast Cancer Diagnosis And Prognosis")
Novel Molecular Biomarkers For Breast Cancer Diagnosis And Prognosis51,99 €![Coffee Powder. The Novel Wound Dressing]( "Coffee Powder. The Novel Wound Dressing")
Coffee Powder. The Novel Wound Dressing34,99 €![Novel mechanisms in the response of tumour cells to iron depletion]( "Novel mechanisms in the response of tumour cells to iron depletion")
Novel mechanisms in the response of tumour cells to iron depletion48,99 €![A novel therapeutic approach for the treatment of cerebral palsy]( "A novel therapeutic approach for the treatment of cerebral palsy")
A novel therapeutic approach for the treatment of cerebral palsy23,99 €![Design of novel compounds with the potential of dual PPAR¿/¿ modulation]( "Design of novel compounds with the potential of dual PPAR¿/¿ modulation")
Design of novel compounds with the potential of dual PPAR¿/¿ modulation55,99 €![A Novel Therapeutic Approach for the Treatment of Brain Atrophy]( "A Novel Therapeutic Approach for the Treatment of Brain Atrophy")
A Novel Therapeutic Approach for the Treatment of Brain Atrophy23,99 €![Novel Revolution in Cancer Therapy and Diagnosis]( "Novel Revolution in Cancer Therapy and Diagnosis")
Novel Revolution in Cancer Therapy and Diagnosis16,99 €
The concept of the cardiovascular continuum, introduced during the early 1990s, created a holistic view of the chain of events connecting cardiovascular-related risk factors with the progressive development of pathological-related tissue remodelling and ultimately, heart failure and death. Understanding of the tissue-specific changes, and new technologies developed over the last 25-30 years, enabled tissue remodelling events to be monitored in vivo and cardiovascular disease to be diagnosed more reliably than before. The tangible product of this evolution was the introduction of a number of biochemical markers such as troponin I and T, which are now commonly used in clinics to measure myocardial damage. However, biomarkers that can detect specific earlier stages of the cardiovascular continuum have yet to be generated and utilised. The majority of the existing markers are useful only in the end stages of the disease where few successful intervention options exist.